Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Vuja De Sciences
AddedFeb 16, 2024
UpdatedJun 18, 2026
Vuja De Sciences

Vuja De Sciences

Seed

Vuja De Sciences: Pioneering cancer treatments using advanced lab tech to prevent progression & recurrence.

HQ
Hoboken, NJ, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to combat cancer metastasis, Vuja De Sciences focuses on preventing cancer progression and recurrence. The company leverages advanced laboratory technologies and Comparative Oncology to develop treatments that target both primary and metastatic tumors. Their innovative approach aims to de-risk and inform product development, enhancing the success rates of human oncology clinical trials. Vuja De Sciences is dedicated to disabling undetected microscopic metastatic tumors, which are often responsible for deadly cancer recurrences.

Notable figures affiliated with Vuja De Sciences include leading experts in oncology and laboratory technology. The company has garnered attention for its pioneering methods in cancer treatment, contributing significantly to the field of metastatic cancer research. By focusing on preclinical endpoints and leveraging Comparative Oncology, Vuja De Sciences has made impactful strides in improving the efficacy of cancer therapies, ultimately aiming to reduce the high mortality rates associated with metastatic cancer.

Vuja De Sciences - Similar Companies

Vyriad logo

Vyriad

vyriad.com

MetasTx logo

MetasTx

metastx.com

OncoPrecision logo

OncoPrecision

oncoprecision.bio

Vanquish Oncology logo

Vanquish Oncology

Novita Pharmaceuticals logo

Novita Pharmaceuticals

novita-pharm.com

Acomhal Research logo

Acomhal Research

Umoja Biopharma logo

Umoja Biopharma

Cancervax logo

Cancervax

cancervax.com

Novasenta logo

Novasenta

novasenta.com

Curelab Oncology logo

Curelab Oncology

Vicus Therapeutics logo

Vicus Therapeutics

TumorGen logo

TumorGen

tumorgen.net

Coare Biotechnology logo

Coare Biotechnology

Vyant Bio logo

Vyant Bio

Volastra Therapeutics logo

Volastra Therapeutics

volastratx.com

Vuja De Sciences - Quick Facts

Who are Vuja De Sciences' competitors?

Companies similar to Vuja De Sciences include Vyriad, MetasTx, OncoPrecision and Vanquish Oncology.

When was Vuja De Sciences founded?

Vuja De Sciences was founded in 2017.

Where is Vuja De Sciences' headquarters located?

Vuja De Sciences' headquarters is located in Hoboken, NJ, US.

How much has Vuja De Sciences raised to-date?

As of Oct 30, 2023, Vuja De Sciences has raised a total of $1.8M (USD).

How many employees does Vuja De Sciences have?

Vuja De Sciences has 7 employees as of Feb 5, 2024.

Vuja De Sciences - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Treatments
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified